Showing 1 - 20 results of 24 for search '"Bromma"', query time: 0.07s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19

    A new recombinant factor VIII: from genetics to clinical use by Kannicht C, Kohla G, Tiemeyer M, Walter O, Sandberg H

    Published 2015-07-01
    “…Christoph Kannicht,1 Guido Kohla,1 Maya Tiemeyer,2 Olaf Walter,3 Helena Sandberg4 1Octapharma Biopharmaceuticals GmbH, Molecular Biochemistry, Berlin, Germany; 2Octapharma Biopharmaceuticals GmbH, Heidelberg, Germany; 3Octapharma AG, Lachen, Switzerland; 4CoaBio AB, Bromma, SwedenThe December 2014 issue of Drug Design, Development and Therapy included a review article by Santagostino entitled “A new recombinant factor VIII: from genetics to clinical use”.1 The article provided a timely review of recent advances and developments in the treatment of hemophilia A with recombinant factor VIII (rFVIII).1 However, when reviewing licensed rFVIII products, Santagostino1 did not include Human-cl rhFVIII (simoctocog alfa, Nuwiq®).2–4 Nuwiq® is a new-generation rFVIII protein produced in HEK 293 F cells that was approved by the European Medicines Agency in July 2014 for the prevention and treatment of bleeds in hemophilia A patients of all ages.5 Read the original article …”
    Get full text
    Article
  20. 20